扫 描 看 全 文
韩海燕, 路建饶, 王新华, 等. 叶氏肾衰甲方对3、4期慢性肾脏病患者肾功能及肾纤维化影响的临床研究[J]. 上海中医药杂志, 2016,50(3):52-55.
HAN Hai-yan, LU Jian-rao, WANG Xin-hua, et al. Clinical study on renal function and renal fibrosis in patients with chronic kidney disease in 3 and 4 phases by “Ye’s renal failure Party A”[J]. Shanghai Journal of Traditional Chinese Medicine, 2016,50(3):52-55.
韩海燕, 路建饶, 王新华, 等. 叶氏肾衰甲方对3、4期慢性肾脏病患者肾功能及肾纤维化影响的临床研究[J]. 上海中医药杂志, 2016,50(3):52-55. DOI:
HAN Hai-yan, LU Jian-rao, WANG Xin-hua, et al. Clinical study on renal function and renal fibrosis in patients with chronic kidney disease in 3 and 4 phases by “Ye’s renal failure Party A”[J]. Shanghai Journal of Traditional Chinese Medicine, 2016,50(3):52-55. DOI:
目的:观察叶氏肾衰甲方治疗3、4期慢性肾脏病的临床疗效。 方法:将60例3、4期慢性肾脏病患者随机分为治疗组与对照组,每组30例。对照组给予西医常规治疗,治疗组在对照组治疗措施基础上加用叶氏肾衰甲方。两组疗程均为6个月,观察临床疗效,比较中医证候积分、24 h尿蛋白定量、肾功能指标、血清人转化生长因子β,1,(TGF-β,1,)的变化情况。 结果:①治疗组、对照组临床总有效率分别为93.33%和53.33%;组间临床疗效比较,差异有统计学意义(P,<,0.05)。②治疗前后组内比较,治疗组中医证候积分值显著下降(P,<,0.05),对照组积分值下降不显著(P,>,0.05)。组间治疗前后差值比较,治疗组中医证候积分下降程度比对照组更加显著(P,<,0.05)。③治疗前后组内比较,两组24 h尿蛋白定量均显著下降(P,<,0.05)。组间治疗后比较,治疗组24 h尿蛋白定量下降程度比对照组更加显著(P,<,0.05)。④治疗前后组内比较,两组BUN、UA水平均无显著差异(P,>,0.05);治疗组Scr水平显著下降(P,<,0.05)、eGFR水平显著上升(P,<,0.05)。组间治疗后比较,Scr、eGFR水平差异有统计学意义,治疗组改善程度优于对照组(P,<,0.05)。⑤治疗前后组内比较,治疗组血清TGF-β,1,水平显著下降(P,<,0.05),对照组无显著差异(P,>,0.05)。组间治疗前后差值比较,血清TGF-β,1,下降水平差异有统计学意义(P,<,0.05)。 结论:叶氏肾衰甲方治疗3、4期慢性肾脏病,可减少蛋白尿,提高肾小球滤过率,减少肾脏纤维化,从而延缓慢性肾脏疾病的进展。
Objective:To study the effect of “Ye’s renal failure Party A” in the treatment of chronic renal failure. Methods3 and 4 period of 60 cases of patients with chronic kidney disease were selected and randomly divided to control group and treatment group, 30 in each group. The patients in control group were treated with normal western medicine, while the treatment group was added “Ye’s renal failure Party A” on the basis of normal western medicine treatment. After 6 months treatment, we observed two groups of patients with TCM syndrome score, 24 hours urine protein, therapeutic efficacy, renal function, serum TGF beta 1. Results:①The total effective rate of the treatment group were 93.33% and the control group were 53.33% respectively. The treatment group TCM syndrome score decreased more significantly than the control group (P,<,0.05). ②TCM syndrome score in the treatment group decreased significantly (P,<,0.05), while the score in the control group did not decrease significantly (P,>,0.05) after the treatment. The difference between the groups, TCM syndrome score in the treatment group decreased more significant than the control group (P,<,0.05). ③Compared before and after treatment, the two groups of 24 h urinary protein were significantly decreased (P,<,0.05). Between two groups, 24 h urinary protein in the treatment group decreased more significantly than the control group (P,<,0.05) after the treatment. ④There was no significant difference in UA and BUN in each group before and after treatment (P,>,0.05); Scr in treatment group was significantly decreased (P,<,0.05) and eGFR was significantly increased (P,<,0.05). There were significant differences in Scr and eGFR between the two groups, and the improvement degree of the treatment group was better than the control group (P,<,0.05). ⑤The serum levels of TGF-β,1, were significantly decreased in the treatment group (P,<,0.05), while there was no significant difference in control group (P,>,0.05). Compared between the two groups after the treatment, the difference was statistically significant between the serum levels of TGF-β,1,(P,<,0.05). Conclusion:“Ye’s renal failure Party A” in the treatment of 3 and 4 chronic kidney disease has obvious curative effect, including reduction proteinuria, improvement renal function and prevention of renal fibrosis.
慢性肾脏病3、4期叶氏肾衰甲方肾功能不全肾纤维化
chronic renal failure3 and 4 phase“Ye’s renal failure Party A”renal insufficiencyrenal fibrosis
0
浏览量
219
下载量
0
CSCD
5
CNKI被引量
关联资源
相关文章
相关作者
相关机构